Medicines safeguard clause: biosimilars and hybrids excluded, 2025 amount M lowered to €26.10bn
Article 31 of the 2026 Social Security Financing Act adds a IV to Article L. 138-10 of the Social Security Code: similar biological medicines (biosimilars) and hybrid medicines are no longer counted in the turnover used for the safeguard clause. It also lowers the amount M set for 2025 by the LFSS 2025 from €27.25bn to €26.10bn.
Measure originators
No official estimate found for this measure.
Measure impact
Companies selling biosimilars and hybrids no longer have these sales included in the safeguard clause base; lowering the 2025 amount M lowers the clause's trigger threshold for 2025.
Official references
Sources
Procedure timeline
Follow the progress of this fiscal measure through the different stages of the parliamentary procedure.
Administrative implementation
Entrée en vigueur de la mesure et mise en œuvre par l'administration
President of the Republic signature
Publication au Journal officiel
National Assembly has the final say
Si échec CMP
Debate and vote
Débat et vote en séance publique à l'Assemblée nationale, ou engagement de la responsabilité du Gouvernement (article 49.3)